Compare OGN & BXMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | BXMX |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | N/A |
| Metric | OGN | BXMX |
|---|---|---|
| Price | $13.31 | $13.26 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.40 | N/A |
| AVG Volume (30 Days) | ★ 15.2M | 142.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 0.60% | ★ 7.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $24.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $13.24 |
| 52 Week High | $13.44 | $15.00 |
| Indicator | OGN | BXMX |
|---|---|---|
| Relative Strength Index (RSI) | 77.58 | 29.96 |
| Support Level | $8.59 | N/A |
| Resistance Level | N/A | $14.64 |
| Average True Range (ATR) | 0.32 | 0.21 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 97.87 | 0.65 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.